儿童使用司美格鲁肽的伦理考量
本文探讨儿童处方司美格鲁肽引发的伦理挑战，聚焦获取障碍、污名化及肥胖结构性决定因素被忽视等问题。司美格鲁肽已在德国、英国、丹麦和阿联酋获批用于成人和儿童肥胖管理，但儿童应用仍存争议。文章提出旨在减少伤害、支持自主、促进儿童健康的临床伦理建议。
要点
- 司美格鲁肽已在德国、英国、丹麦和阿联酋获批用于儿童肥胖管理。
- 支持者认为可降低心血管风险并预防肥胖相关疾病。
- 批评者担忧长期安全性、疗效及对儿童发育的影响。
核心结论
- 儿童使用司美格鲁肽存在伦理争议，需关注获取障碍、污名化及肥胖的结构性决定因素，并提出减少伤害、支持自主、促进儿童健康的伦理建议。
主要发现
- 司美格鲁肽以Ozempic、Wegovy和Rybelsus商品名销售，2021年最初获批用于成人2型糖尿病。
- 该药现已在德国、英国、丹麦和阿联酋获批用于成人和儿童肥胖管理。
- 支持者强调其可降低心血管风险并预防肥胖相关疾病，批评者担忧长期安全性、疗效及对儿童发育的影响。
临床怎么用
- 临床医生在处方前应审视获取障碍、污名化及肥胖的结构性决定因素。
- 伦理建议旨在减轻伤害、支持患儿自主并促进儿童健康。
以上解读依据论文摘要（全文未开放获取或许可不允许翻译转载）。
原文
Semaglutide, marketed as Ozempic, Wegovy and Rybelsus, has rapidly become one of the most prominent medications of recent years. Initially approved in 2021 for type 2 diabetes in adults, semaglutide is now authorised for obesity management in adults and children in several countries, including Germany, the UK, Denmark and the United Arab Emirates. Despite this broad regulatory approval, its paediatric use remains a subject of debate. Advocates highlight its potential to reduce cardiovascular risk and prevent obesity-related illness, while critics emphasise uncertainties about long-term safety, efficacy and impacts on child development. This paper examines the ethical challenges raised by prescribing semaglutide to children, focusing on access barriers, stigma and the neglect of structural determinants of obesity, and provides ethical recommendations for clinicians aimed at mitigating harm, supporting autonomy and promoting children’s health.
引用
- Archives of Disease in Childhood：Ethical considerations for semaglutide use in children
供执业医师工作参考，不替代临床判断；数值与分级以指南原文为准。